Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection

a technology of adrenergic receptor and filler, which is applied in the field of injectable combination of adrenergic receptor agonists and fillers, can solve problems such as dissuasion of some patients, and achieve the effects of reducing oedema and swelling, and hindering liquid concentration

Inactive Publication Date: 2015-11-12
GALDERMA RES & DEV SNC
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a method for reducing or avoiding b bruising, bleeding, and inflammation in aesthetic procedures such as dermal fillers. This is achieved by providing an individual in need thereof a quantity of an adrenergic receptor agonist, such as brimonidine, which has been shown to decrease or avoid erythema, ecchymosis, and bruising. When the composition further contains an anaesthetic, the efficiency of the anaesthetic is improved due to the vasoconstrictive effect provided by the α adrenergic agonist, which limits anaesthetic diffusion in a large area, thus making it efficient in the strict injection site. The reduction of inflammation results in a longer-lasting filler due to its slower degradation, and a reduction of oedema and swelling is observed for the same reason.

Problems solved by technology

This kind of drawbacks may discourage some patients and particularly towards aesthetic procedures.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
  • Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection

Examples

Experimental program
Comparison scheme
Effect test

examples

LEGENDS TO FIGURES

[0070]FIG. 1 shows the Irritating Primary Index (IPI) evolution between Day 0 and Day 8 for the claimed composition (Test2) in comparison with a filler alone (Test1).

[0071]FIG. 2 shows the total score of inflammatory reaction at Day 8 for the claimed composition (Test2) in comparison with a filler alone (Test1).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and / or inflammation.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of co-pending U.S. patent application Ser. No. 13 / 322,803 filed Feb. 7, 2012, which is a national stage application under 35 U.S.C. §371 of PCT Application No. PCT / EP2010 / 057493, filed May 28, 2010, which claims priority to and the benefit of U.S. provisional patent application Ser. No. 61 / 213,322, filed May 29, 2009, each of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention is in the surgical and dermatological domain.[0003]The present invention relates to an injectable composition comprising an adrenergic receptor agonist, preferably brimonidine, and a filler, preferably hyaluronic acid. It concerns its use in preventing and / or treating superficial bruising and bleeding caused by aesthetic procedures.BACKGROUND OF THE INVENTION[0004]Superficial bruising and, to a lesser extent, bleeding are not uncommon consequences—reported on average about one...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/498A61K31/167A61K38/16A61L27/20A61L27/54
CPCA61K31/498A61L27/20A61L27/54A61K38/164A61L2300/40A61L2400/06A61L2300/402A61L2300/204A61K31/167A61K9/0014A61K31/00A61K31/728A61K45/06A61P7/04A61P17/00A61P17/02A61P29/00A61P43/00A61K2300/00A61K9/08
Inventor BERTHOLON, ISABELLEBRUNEL, FLORENCEHERBAGE, BENJAMINVILLARD, CHRISTOPHE
Owner GALDERMA RES & DEV SNC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com